Data reveal injectable monitor measures tissue oxygen level changes in response to standard-of-care procedures, showing potential to help monitor disease progression and guide clinical management for peripheral artery disease

26 January 2019 Written by CN1699 Services Article viewed 21 times (0 times in the last week)

Profusa announced promising clinical data from two studies evaluating the company's Lumee Oxygen Platform, an injectable tissue integrated biosensor and an intelligent data platform intended for continuous, real-time monitoring of tissue oxygen levels.

The device received CE Mark in October 2016 for continuous monitoring of tissue oxygen and is CE Marked for sale in the EU for monitoring tissue-oxygen perfusion as a general indication. In the U.S., it is limited by federal law to investigational use.

For more information, visit: Dicardiology

PROFUSA is a medical devices company creating tissue-integrated sensors for chronic disease management and healthy living.

Read more related topics:

Artery Disease | Cardiology

Source: Dicardiology

Grace T

Managing Editor - CN1699 Services